Abstract 423P
Background
Nodular, acral, and mucosal melanomas that represent non-cumulative sun damage lesions account for more than 60% of melanomas in Asia but comprise only 4% in Caucasians. The distinct spectrum of manifestations might influence the clinical course and outcomes. Factors associated with the prognosis of high-risk resected melanomas from Indonesia have not yet been previously reported.
Methods
Demographic, clinical, pathological characteristics of 82 melanoma patients who underwent complete resection in 2014-2019 were analyzed.
Results
Nodular melanoma (NM), mucosal melanoma (MM), and acral lentiginous melanoma (ALM) made up of 42.7% (n=35), 42.7% (n=35), and 14.2% (n=12) of cases, respectively. Most patients were diagnosed at advanced stages (76.8%, n=63 at Stage III-IV). For cutaneous melanomas, 89% (N=42) patients were found with Breslow’s tumor thickness more than 4 mm, 51% (N=24) with ulceration, 93% (N=43) with diameter more than 6 mm, 59% (N=28) with lymphovascular invasion, and 74% (N=35) with regional lymph node infiltration. In mucosal melanomas, 14.5% (N=5) were diagnosed with regional spread to lymph nodes and 77% cases (N=27) were found with regional infiltration beyond mucosa. Regional lymph node spread was associated with shorter overall survival (median survivals were 17 vs 23.4 months, Mantel-Cox test p=0.049). Patients diagnosed at T4 were also associated with poor overall survival (median survivals were 23 vs 32 months, Mantel-Cox test p=0.047).
Conclusions
Most melanoma patients in Indonesia were found as a higher risk for recurrence after the initial complete resection. Regional lymph node infiltration and thicker tumor (T4) were associated with poor prognosis. Early detection and advancement of treatment strategy are required to improve the survivals of melanoma patients in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sumadi Lukman Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session